Stocktoria
NUTRA PHARMA CORP NPHC
NUTRA PHARMA CORP (NPHC) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $257,612 at a -794.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1995 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NPHC | NUTRA PHARMA CORP | 3/9 | — | — | — |
| NTRR | NEUTRA CORP. | 4/9 | — | — | — |
| RAJAF | Cordyceps Sunshine Biotech Holdings Co., Ltd. | 4/9 | -6.82 | — | — |
| PLSH | PANACEA LIFE SCIENCES HOLDINGS, INC. | 4/9 | -13.95 | — | — |
| FTLF | FITLIFE BRANDS, INC. | 3/9 | 1.99 | 51.6 | -75.3% |
| BON | Bon Natural Life Ltd | 4/9 | 4.25 | — | -21.7% |
| CHUC | Charlie's Holdings, Inc. | 3/9 | -1.35 | 13.2 | — |
About NUTRA PHARMA CORP
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin/Nyloxin Extra Strength, an over-the-counter (OTC) pain reliever; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, overthecounter pain reliever to treat moderate to severe chronic pain in companion animals; Equine Pain-Away, an OTC topical pain reliever to relieve pain in horses; and Luxury Feet, an OTC pain reliever for foot pain from high heels and stilettos. It is also involved in developing RPI-78M to treat neurological and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, and general anti -viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Boca Raton, Florida.
FAQ
Is NPHC financially healthy?
NUTRA PHARMA CORP's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does NPHC pay a dividend?
No, NUTRA PHARMA CORP does not currently pay a dividend.
How profitable is NPHC?
In FY2025, NUTRA PHARMA CORP had a net margin of -794.8%.
Is NPHC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NUTRA PHARMA CORP: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.